David B. Feirstein - Partner

PDF Print Friendly Page
David B. Feirstein

Download V-Card

New York
Phone: +1 212-446-4861
Fax: +1 212-446-4900
Overview News Publications

Professional Profile

David Feirstein’s practice concentrates on mergers and acquisitions, corporate and securities law matters and corporate governance. David is recognized in Chambers USA: America’s Leading Lawyers for Business in 2016, which said “he is a superstar; he is incredibly smart and very efficient.” He was also recognized in 2016 and 2014 as a “Rising Star” by Law360 for Mergers & Acquisitions, in The Legal 500 U.S. for M&A: Large Deals ($1bn+) in 2015 and by Super Lawyers for his corporate practice.

David also teaches a class as an adjunct professor at NYU Law on negotiating corporate transactions.


Representative Matters

David has advised clients on numerous significant matters, including the following:

  • Celator Pharmaceuticals in its $1.5 billion sale to Jazz Pharmaceuticals

  • Accenture in its joint venture with Apax Partners from the carve out of Accenture’s Duck Creek Technologies insurance claims, billing and policy administration software business

  • Nexstar Broadcasting Group in connection with its unsolicited takeover proposal for Media General in the face of Media General’s proposed acquisition of Meredith Corp., resulting in Nexstar’s pending $4.6 billion acquisition of Media General and the termination of the proposed merger transaction between Meredith and Media General

  • Accenture in its $830 million carve-out sale of Navitaire to Amadeus IT Holding SA

  • IGATE Corporation in its $4 billion sale to Cap Gemini

  • Burger King Worldwide Inc. in its $13.3 billion merger transaction with Tim Hortons Inc.

  • Infineon Technologies AG in its $3 billion acquisition of International Rectifier Corporation

  • Lazard as financial advisor to Reynolds American in its $27.4 billion acquisition of Lorillard

  • Bristol-Myers Squibb in its $725 million (including milestone payments) acquisition of iPierian, a privately-held biotech company

  • Beechcraft in its $1.4 billion sale of the company to Textron Inc.

  • rue21, inc. in the $1.1 billion sale of the company to Apax Partners

  • 3G Capital Partners Ltd. in its $28.0 billion acquisition, along with Berkshire Hathaway Inc., of H. J. Heinz Company

  • Clearwire Corporation in Sprint’s acquisition of the stake in Clearwire which Sprint did not already own, implying a $14 billion enterprise value for Sprint and the unsolicited competing offer for Clearwire by DISH Networks

  • Danaher Corporation in its $338 million acquisition of IRIS International, Inc.

  • GeoEye in its merger with DigitalGlobe

  • Bristol-Myers Squibb in its $7 billion acquisition of Amylin Pharmaceuticals and joint collaboration with AstraZeneca plc

  • Burger King Worldwide Holdings, Inc. and its controlling stockholder, 3G Capital Partners Ltd., in connection with a business combination with Justice Holdings Ltd., a London Stock Exchange-listed public investment vehicle, resulting in a partial sale of Burger King to the Justice shareholders for $1.4 billion and a New York Stock Exchange listing of Burger King

  • Bristol-Myers Squibb Company in its $2.5 billion acquisition of Inhibitex, Inc.

  • Colgate-Palmolive Company in its €672 million acquisition of Sanex Brands from Unilever and related $210 million disposition of Colgate’s Colombian detergents business

  • Mirant Corporation in its $3.1 billion merger of equals with RRI Energy, Inc.

  • PVH in its $3 billion acquisition of Tommy Hilfiger

  • MetLife in the recapitalization and split-off of its less than wholly owned subsidiary, RGA

  • Apollo in its $16 billion buyout of Harrah’s with TPG

  • Iscar in its $4 billion acquisition by Berkshire Hathaway

  • ConocoPhillips in its multi-billion dollar oil sands joint venture with EnCana

  • ConocoPhillips in its $35 billion acquisition of Burlington Resources

© 2016 Kirkland & Ellis LLP